drugset / Trial / NCT06434961

The Trial of SHR6508 in Secondary Hyperparathyroidism

NCT06434961

Phase 3 Completed 498 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

Timeline

Start
2024-06-14
Primary completion
2025-09-29
Completion
2025-11-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cinacalcet Other / unclassified
Subject SHR6508 Unknown